Marina Biotech Inc, formerly MDRNA, Inc., is a biotechnology company focused on the discovery, development and commercialization of pharmaceuticals based on RNA interference (RNAi). Its infrastructure provides for pre-clinical scale manufacturing of both siRNAs and delivery materials, the analysis and optimization of these compounds both individually and as drug candidates, and the filing of Investigational New Drug Applications. The Company develops RNAi-based product candidates for the treatment of cancer, metabolic disorders, inflammation, and viral infections. It focuses on siRNA constructs, such as dicer substrates and three-stranded meroduplexes, and delivery systems for improved siRNA delivery. MDRNA's various development programs consist of oncology; metabolic disorders, and inflammation.